NHP POC
Pipeline
Research programs of Clayton Foundation and its supporting organizations have led to several FDA approved drugs, medical devices and diagnostic assays along with the following pipeline in development by our licensees. We also have technologies and preclinical projects that are available for licensing.
Available for Licensing
DHS Fc Domain
Fc domain for antibody half-life extension
Cyspondin
LGR Targeting Protein Drug Conjugate
Preclinical
Partnered
ArboShield™ - DV
Biological (insect) vaccination for Dengue
ArboShield™ - ZK
Biological (insect) vaccination for Zika
ArboShield™ - CV
Biological (insect) vaccination for Chikungunya
ArboShield™ -YV
Biological (insect) vaccination for Yellow Fever Virus
GrB-Fc-IT4 (Targets Fn14)
Oncology - solid tumors
Phase 1 planned
GrB-Fc-Anti-Fra (Folate Receptor A)
Oncology - Gastrointestinal, Gynecological, Breast, Lung, Head & Neck, Leukemias, Lymphomas
IND enabling
GrB-Fc-VEGF (Targets KDR/VEGFR2)
Oncology - solid tumors
Ophthalmology - wet AMD & Choroidal Neovascularization
IND enabling
GrB-Fc-4D5 (Targets Her2/Neu)
Oncology - Breast, Gallbladder, Bladder, Esophageal/Gastric Junction, Stomach
IND enabling
RT-200
Indication: Type II Diabetes
Phase 1/2a planned